A meta-analysis of two randomized, double-blind, placebo-controlled, phase III studies in patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK/ZK to determine clinical benefit on progression-free survival (PFS) in high LDH pts.

A meta-analysis of two randomized, double-blind, placebo-controlled, phase III studies in patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK/ZK to determine clinical benefit on progression-free survival (PFS) in high LDH pts.

Show other versions (1)
Bibliographic Details
Main Authors: Major, P, Trarbach, T, Lenz, H, Kerr, D, Pendergrass, K, Douillard, J, Chen, B, Laurent, D, Jacques, C, Van Cutsem, E
Format: Conference item
Published: 2006

Similar Items